BR112022011857A2 - Derivado de pirimidina substituído por deutério e composição farmacêutica compreendendo o mesmo - Google Patents

Derivado de pirimidina substituído por deutério e composição farmacêutica compreendendo o mesmo

Info

Publication number
BR112022011857A2
BR112022011857A2 BR112022011857A BR112022011857A BR112022011857A2 BR 112022011857 A2 BR112022011857 A2 BR 112022011857A2 BR 112022011857 A BR112022011857 A BR 112022011857A BR 112022011857 A BR112022011857 A BR 112022011857A BR 112022011857 A2 BR112022011857 A2 BR 112022011857A2
Authority
BR
Brazil
Prior art keywords
pyrimidine derivative
substituted pyrimidine
pharmaceutical composition
same
deuterium
Prior art date
Application number
BR112022011857A
Other languages
English (en)
Inventor
Kim Sung-Eun
Lee Sunho
Rajesh Rengasamy
Hyub Lee Yong
Jeong Kong Yun
Original Assignee
Oncobix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobix Co Ltd filed Critical Oncobix Co Ltd
Publication of BR112022011857A2 publication Critical patent/BR112022011857A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

DERIVADO DE PIRIMIDINA SUBSTITUÍDO POR DEUTÉRIO E COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO. A presente invenção fornece: um novo composto derivado de pirimidina substituído por deutério representado pela Fórmula 1 ou um sal farmaceuticamente aceitável do mesmo; e uma composição farmacêutica para tratamento de câncer de pulmão compreendendo o mesmo. Particularmente, o composto derivado de pirimidina substituído por deutério representado pela Fórmula 1 inibe eficazmente o crescimento de células cancerígenas com mutação em ALK e EGFR.
BR112022011857A 2019-12-16 2020-12-15 Derivado de pirimidina substituído por deutério e composição farmacêutica compreendendo o mesmo BR112022011857A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190167769 2019-12-16
PCT/KR2020/018385 WO2021125758A1 (ko) 2019-12-16 2020-12-15 신규한 중수소 치환 피리미딘 유도체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
BR112022011857A2 true BR112022011857A2 (pt) 2022-09-06

Family

ID=76477576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011857A BR112022011857A2 (pt) 2019-12-16 2020-12-15 Derivado de pirimidina substituído por deutério e composição farmacêutica compreendendo o mesmo

Country Status (9)

Country Link
US (1) US20230114177A1 (pt)
EP (1) EP4079730A4 (pt)
JP (1) JP2023507943A (pt)
KR (1) KR20220113933A (pt)
CN (1) CN114829352A (pt)
AU (1) AU2020406819B2 (pt)
BR (1) BR112022011857A2 (pt)
CA (1) CA3160150A1 (pt)
WO (1) WO2021125758A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54533B1 (en) * 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
EP2276747A1 (en) * 2008-03-11 2011-01-26 Cellzome Limited Sulfonamides as zap-70 inhibitors
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
WO2015038868A1 (en) * 2013-09-13 2015-03-19 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivatives
US10106507B2 (en) * 2014-08-03 2018-10-23 H. Lee Moffitt Cancer Center and Research Insitute, Inc. Potent dual BRD4-kinase inhibitors as cancer therapeutics
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
WO2019112344A1 (ko) * 2017-12-07 2019-06-13 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
KR101992621B1 (ko) * 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019190259A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
WO2023056423A1 (en) * 2021-09-30 2023-04-06 Essa Pharma, Inc. Androgen receptor modulators and methods for use as bifunctional degraders

Also Published As

Publication number Publication date
JP2023507943A (ja) 2023-02-28
AU2020406819B2 (en) 2023-11-09
KR20220113933A (ko) 2022-08-17
CN114829352A (zh) 2022-07-29
EP4079730A1 (en) 2022-10-26
US20230114177A1 (en) 2023-04-13
WO2021125758A1 (ko) 2021-06-24
EP4079730A4 (en) 2023-11-29
AU2020406819A1 (en) 2022-06-16
CA3160150A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CR20220354A (es) Inhibidores de egfr
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
CY1120072T1 (el) 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
BR112021023136A2 (pt) Compostos heterocíclicos, métodos de preparação e usos dos mesmos
EA201792214A1 (ru) Соединения замещенного хиназолина
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2020007947A (es) Inhibidores de erbb/btk.
BR112018015413A2 (pt) inibidores de indoleamina-2,3-dioxigenase (ido)
EA201991884A2 (ru) Ингибиторы g12c kras
WO2016060443A3 (en) Compounds and compositions for modulating egfr mutant kinase activities
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
EA201000886A1 (ru) Органические соединения
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2018009913A (es) Aglutinantes max como moduladores myc y sus usos.
CR20210375A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
BR112021023927A2 (pt) Composto, e, composição farmacêutica